US Veteran’s Administration to Cover Alzheimer’s Drug Leqembi

The US Veteran’s Administration has decided that it will cover Leqembi, Eisai and Biogen’s new therapeutic for Alzheimer’s disease. The announcement comes just weeks after the Centers for Medicare and Medicaid Services (CMS) decided not to expand coverage of the drug to patients outside of clinical trials, a restriction put in place after last year’s approval and failed market release of Aduhelm.

According to Kevin Dunleavy, “Approved under the FDA’s accelerated pathway two months ago, Leqembi costs $26,000 annually. The drug, which is infused twice a month, targets brain plaque. The FDA  has set a target date of July 6 to decide whether to grant Leqembi a full approval. If it passes muster, Medicare officials would then deliberate over the agency’s coverage policies.”

To read more, click here.

(Source: Fierce Pharma, March 14^th, 2023)